Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Nefopam Prices Continue To Cause Pain

Pricewatch UK – January 2020

Executive Summary

Continuing UK price rises were seen for nefopam in January, according to the latest figures from market researcher WaveData.

You may also be interested in...



UK Imipramine Prices Double In December

December brought price rises for the UK generics market that included imipramine prices as much as doubling and a leap of more than two-thirds in the average price of frovatriptan tablets.

Concessions Hit And Miss As Some UK Prices Treble

Concession prices granted by the UK Department of Health and Social Care targeted some, but not all, of the fastest-rising generics prices in November. The average cost of some presentations more than trebled, according to the latest figures from WaveData.

Beximco And Mylan Strike Biosimilars Deal

Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.

Topics

UsernamePublicRestriction

Register

GB149612

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel